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Abstract
Mice with a deficiency in IFN-γ or IFN-γ receptor (IFN-γR) are
more susceptible to collagen-induced arthritis (CIA), an
experimental autoimmune disease that relies on the use of
complete Freund's adjuvant (CFA). Here we report that the
heightened susceptibility of IFN-γR knock-out (KO) mice is
associated with a functional impairment of CD4+CD25+ Treg
cells. Treatment of wild-type mice with depleting anti-CD25
antibody after CFA-assisted immunisation with collagen type II
(CII) significantly accelerated the onset of arthritis and increased
the severity of CIA. This is an indication of a role of Treg cells in
the effector phase of CIA. IFN-γR deficiency did not affect the
number of CD4+CD25+ T cells in the central and peripheral
lymphoid tissues. In addition, CD4+CD25+ T cells isolated from
naive IFN-γR KO mice had a normal potential to suppress T cell
proliferation in vitro. However, after immunisation with CII in
CFA, the suppressive activity of CD4+CD25+ T cells became
significantly more impaired in IFN-γR-deficient mice. Moreover,
expression of the mRNA for Foxp3, a highly specific marker for
Treg cells, was lower. We further demonstrated that the effect of
endogenous IFN-γ, which accounts for more suppressive
activity in wild-type mice, concerns both Treg cells and accessory
cells. Our results demonstrate that the decrease in Treg cell
activity in CIA is counter-regulated by endogenous IFN-γ.
Keywords: arthritis, autoimmunity, interferon-γ, regulatory T cells
Introduction
The adaptive immune system uses various potent effector
mechanisms for the elimination of foreign pathogens.
Because these mechanisms are potentially damaging to
the host, an essential feature of the immune system is its
ability to distinguish self from non-self antigens and to
develop tolerance to the former. With regard to T cell toler-
ance, the immune system has evolved several strategies.
Most autoreactive T cells are eliminated during (primary)
maturation in the thymus, a process described as negative
selection, resulting in central T cell tolerance. Autoreactive
T cells that escape negative selection will nevertheless be
prevented from being activated as they are confronted with
auto-antigen in the periphery. Several mechanisms have
been proposed to account for this peripheral tolerance.
One of those is suppression by a subset of T cells that
express both CD4 and CD25. Evidence for the important
role of these cells is overwhelming [1]. For example, when
CD4+ T cells isolated from peripheral lymphoid tissues of
normal mice are depleted of CD4+CD25+ T cells and
injected into nu/nu mice, the recipients develop a high inci-
dence of organ-specific autoimmune disease [2]. Co-trans-
ACs = accessory cells; CFA = complete Freund's adjuvant; CIA = collagen-induced arthritis; CII = collagen type II; CTLA = cytolytic T lymphocyte-
associated antigen; ELISA = enzyme-linked immunosorbent assay; fetal calf serum = FCS; FITC = fluorescein isothiocyanate; GITR = glucocorticoid-
induced tumour necrosis factor receptor; IFN-γ = interferon-γ; IFN-γR KO = interferon-γ receptor knock-out; IL = interleukin; MACS = magnetic-acti-
vated cell sorting; PBS = phosphate-buffered saline; RT-PCR = reverse transcriptase polymerase chain reaction; STAT = signal transduction and 
activators of transcription; Teff = effector T; TGF = transforming growth factor; TLR = Toll-like receptor; Treg = regulatory T.Arthritis Research & Therapy    Vol 7 No 2    Kelchtermans et al.
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fer of the CD4+CD25+ population prevents the induction of
disease. CD4+CD25- and CD4+CD25+ T cells are there-
fore often designated as, respectively, Teff and Treg cells.
CD4+CD25+ Treg cells are generated in the thymus. Their
development is directed by relatively high-avidity interac-
tions between the TCR and self-peptide ligands [3-5]. The
CD4+CD25+ Treg cell population constitutes 5 to 10% of
the mature CD4+ cell population in the adult thymus and
the peripheral lymphoid tissue and blood.
In vitro, CD4+CD25+ Treg cells inhibit polyclonal T cell acti-
vation [6,7]. The suppression is mediated by a cytokine-
independent, cell contact-dependent mechanism that
requires activation of the CD4+CD25+ cells via the TCR
with specific antigen [8]. However, once stimulated, they
are competent to suppress in an antigen-independent man-
ner. Although the exact mechanism by which Treg cells exert
their regulatory function is still unknown, there are indica-
tions that interaction of transforming growth factor-β (TGF-
β) with its receptor [9-11], inhibition of IL-2 production [6]
or downregulation of co-stimulatory molecules on antigen-
presenting cells [12] could be involved.
Treg cells have proved to be important in various animal
models of autoimmune diseases. Administration of anti-
CD25 antibody in vivo induces organ-localised autoim-
mune diseases [13]. Inoculation of CD4+ T cells depleted
of CD25+ cells in nu/nu mice results in autoimmune dis-
eases such as gastritis, thyroiditis and insulitis [2]. Thus,
transfer of Treg cells prevents autoimmune gastritis after
neonatal thymectomy, and inhibits gastritis induced by H/K
ATPase-reactive effector T cells [14]. MBP-specific
CD25+CD4+  T cells prevent spontaneous autoimmune
encephalomyelitis in TCR-transgenic mice deficient in the
recombination activating gene RAG-1 [15]. Similarly,
CD4+CD25+ Treg cells suppress central nervous system
inflammation during active experimental autoimmune
encephalomyelitis [16].
Collagen-induced arthritis (CIA) is a well-described animal
model for rheumatoid arthritis. The disease is induced in
genetically susceptible DBA/1 mice by immunisation with
collagen type II (CII), and both T cell and B cell autoimmune
responses are required for its development [17-19]. IFN-γ
receptor knock-out (IFN-γR KO) mice have been found to
suffer an accelerated and more severe form of CIA [20-23].
Moreover, knocking-out of the IFN-γ gene makes geneti-
cally resistant strains of mice susceptible to CIA [24,25].
These data indicate that deletion of the IFN-γ response
somehow disrupts an endogenous protective mechanism
against CIA.
Morgan and colleagues [26] have recently demonstrated
that CD25+ Treg cells are important in the pathogenesis of
CIA. In the present study we confirmed the importance of
Treg cells in the pathogenesis of CIA by rendering wild-type
DBA/1 mice deficient in Treg cells by depleting anti-CD25
antibodies. Anti-CD25-treated mice developed a signifi-
cantly more severe arthritis, comparable to the disease
course in IFN-γR KO mice. Thus, we proposed that the
higher susceptibility of IFN-γR KO DBA/1 mice to CIA
might be ascribed to defects in the production (differentia-
tion and homeostasis) or function of these CD4+CD25+
Treg cells. We therefore determined the numbers of Treg
cells in central and peripheral lymphoid organs of IFN-γR
KO and wild-type mice. We further investigated whether
Treg cells of IFN-γR KO mice have defects in the ability to
suppress TCR-induced in vitro proliferation of CD4+CD25-
Teff cells.
Materials and methods
Mice and experimental conditions
The generation and the basic characteristics of the mutant
mouse strain (129/Sv/Ev) with a disruption in the gene
coding for the α-chain of the IFN-γ receptor (IFN-γR KO)
have been described [27]. These IFN-γR KO mice were
backcrossed with DBA/1 wild-type mice for 10 generations
to obtain the DBA/1 IFN-γR KO mice used in the present
study. The homozygous IFN-γR KO mice were identified by
PCR as described [23]. Wild-type and IFN-γR KO DBA/1
mice were bred in the Experimental Animal Centre of the
University of Leuven. The experiments were performed in
mice 6 to 10 weeks old, but in each experiment the mutant
and wild-type mice were age-matched within 5-day limits.
The male : female ratio was kept between 0.8 and 1.3 in
each experiment group, unless otherwise mentioned. All
animal experiments were approved by the local ethical
committee (University of Leuven).
Induction and clinical assessment of arthritis
Native chicken CII (Sigma-Aldrich, St Louis, MO, USA) was
dissolved at 2 mg/ml in PBS containing 0.1 M acetic acid
by stirring overnight at 6°C and emulsified in an equal vol-
ume of complete Freund's adjuvant (CFA; Difco Laborato-
ries, Detroit, MI, USA) with added heat-killed
Mycobacterium butyricum (0.5 mg/ml). IFN-γR KO and
wild-type mice were sensitised with a single intradermal
injection at the base of the tail with 100 µl of the emulsion
on day 0. From day 0 after immunisation, mice were exam-
ined for signs of arthritis five times a week. The disease
severity was recorded with the following scoring system for
each limb: score 0, normal; score 1, redness and/or swell-
ing in one joint; score 2, redness and/or swelling in more
than one joint; score 3, redness and/or swelling in the
entire paw; score 4, deformity and/or ankylosis.
Media, reagents and antibodies
All cells were grown in RPMI 1640 (Bio Whittaker Europe,
Verviers, Belgium), supplemented with 10% heat-inacti-
vated FCS (Gibco, Paisley, UK), penicillin (100 IU/ml;Available online http://arthritis-research.com/content/7/2/R402
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Continental Pharma, Brussel, Belgium), streptomycin (100
µg/ml; Continental Pharma), 2 mM L-glutamine, 10 mM
Hepes (Gibco), 0.1 mM nonessential amino acids (ICN,
Asse Relegem, Belgium), 1 mM sodium pyruvate (Gibco)
and 50 µM 2-mercaptoethanol (Fluka, AG, Switzerland).
Anti-CD25 IL-2Rα monoclonal antibody was produced by
hybridoma PC61 in an INTEGRA CELLine CL1000 (Elsco-
lab, Kruibeke, Belgium) and is a rat IgG1 antibody. The
hybridoma supernatant was purified by Protein G-Sepha-
rose chromatography (Amersham Biosciences, Roosend-
aal, The Netherlands) for administration in vivo.
The hamster monoclonal antibody, directed against the
mouse CD3 complex, was prepared from the culture super-
natant of 145-2C11 hybridoma cells [28]. The antibodies
were purified by affinity chromatography with Protein A-
Sepharose (Amersham Biosciences). Batches of anti-CD3
antibody were tested for endotoxin content with the Limu-
lus amebocyte lysate QCL-1000 kit (Bio Whittaker) and
were found to contain less than 3 ng/ml endotoxin.
Cell purification
Lymph nodes (axillary, inguinal and mesenteric) and
spleens were harvested from mice 6 to 8 weeks old. Lymph
nodes and spleens were gently cut into small pieces and
passed through cell strainers (Becton Dickinson Labware,
Franklin Lakes, NJ, USA). Red blood cells were lysed by
two consecutive incubations (5 and 3 min at 37°C) of the
suspension in NH4Cl (0.83% in 0.01 M Tris-HCl, pH 7.2).
Remaining cells were washed, resuspended in cold PBS
and counted. Lymph node preparations were then enriched
for CD4+ T cells with the Mouse T cell CD4 Subset Column
Kit (R&D systems, Abingdon, UK). To purify CD4+CD25+
and CD4+CD25- cells, the enriched CD4+ T cells were
incubated for 20 min at 4°C with FITC-conjugated anti-
CD25 and phycoerythrin (PE)-conjugated anti-CD4 anti-
bodies (10 µg per 108 cells) in PBS containing 2% FCS.
They were sorted by flow cytometry on a FACS Vantage
(Becton Dickinson, San Jose, CA, USA). The resultant
purity of the CD4+CD25- population was 99%, whereas
the purity of the CD4+CD25+ population varied from 96%
to 99%. Alternatively, CD4+ T cells were labelled with PE-
conjugated anti-CD25 monoclonal antibody, followed by
incubation with magnetic-activated cell sorting (MACS)
anti-PE beads (CD25 Microbead Kit; Miltenyi Biotec, Ber-
gisch Gladbach, Germany). CD4+CD25+  T cells were
selected on an LS column in a magnetic field and the flow-
through was collected as CD4+CD25-  T cells. After
removal of the column from the magnetic field,
CD4+CD25+ T cells were flushed out by a plunger. The
purity of the CD4+CD25- population was 99% and the
purity of the CD4+CD25+ population varied from 90% to
95%.
T cell-depleted spleen suspensions were prepared by
MACS (Miltenyi Biotec) and used as accessory cells
(ACs). For MACS separation, the cell suspension was
magnetically labelled with CD90 (Thy1.2) microbeads and
passed through a CS separation column, placed in a mag-
netic field. The unlabelled CD90- cells ran through.
Flow cytometry
Single-cell suspensions (5 × 105 cells) were incubated for
15 min with the Fc-receptor-blocking antibodies anti-
CD16/anti-CD32 (CD16/CD32; BD Biosciences
Pharmingen, San Diego, CA, USA). Cells were washed
with PBS containing 2% FCS and stained with the indi-
cated FITC-conjugated antibodies (0.5 µg) for 30 min,
washed twice and incubated for 30 min with the indicated
PE- or biotin-conjugated antibodies. For the biotin-conju-
gated antibodies, a third staining step with streptavidin
conjugated with peridinin chlorophyll a  protein (PerCP)
was performed. After washing, propidium iodide (Sigma-
Aldrich) was added at a final concentration of 4 µg/ml to
distinguish dead cells from living cells. Biotin-conjugated
anti-CD25 (7D4), FITC-conjugated anti-CD25 (7D4),
FITC-conjugated CD69 (H1.2F3), PE-conjugated anti-
CD4 (RM4-5) and PerCP-conjugated streptavidin were
purchased from BD Biosciences Pharmingen. FITC-conju-
gated anti-CD62L (MEL-14) and anti-CD44-FITC (IM7.8.1)
were from CALTAG Laboratories (Burlingame, CA, USA).
For intracellular staining with anti-CTLA-4-PE (UC10-
4F10-11; BD Biosciences Pharmingen), 106 cells were
first labelled with anti-CD25-FITC as described above.
Then, cells were fixed, permeabilised and stained with anti-
CTLA-4-PE using the Cytofix/Cytoperm™ Kit (BD Bio-
sciences Pharmingen) according to the recommendations
of the manufacturers.
Flow-cytometric analysis was performed on a FACScan
flow cytometer with Cell Quest software (Becton
Dickinson).
Proliferation assays
CD4+CD25- cells (5 × 104 per well) were cultured in U-bot-
tomed 96-well plates (200 µl) with ACs (5 × 104 per well,
30 Gy γ-irradiated or treated with mitomycin-C (Sigma-
Aldrich)), 3 µg/ml anti-CD3 and the indicated numbers of
CD4+CD25+ cells for 48 hours at 37°C in 7% CO2. Cul-
tures were pulsed for the last 16 hours with 1 µCi of
[3H]TdR and harvested. The suppressive activity of the Treg
cells can be presented by plotting the percentage of inhibi-
tion (100 × (Radioactivity in condition without Treg cells –
Radioactivity in condition with Treg cells)/Radioactivity in
condition without Treg cells) against the number of Treg cells.Arthritis Research & Therapy    Vol 7 No 2    Kelchtermans et al.
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Antibody administration
DBA/1 mice were immunised with CII in CFA; 13 days after
immunisation, the mice were treated every second day with
0.25 mg of anti-CD25 (PC61) or control IgG antibodies,
for 4 weeks (injected intraperitoneally).
Histological examination
Forelimbs and hindlimbs were fixed in 10% formalin and
decalcified with formic acid (31.5% (v/v) formic acid and
13% (w/v) sodium citrate). The paraffin sections were
stained with haematoxylin and eosin.
Measurement of serum anti-CII antibodies
Blood samples were taken from the orbital sinus and were
allowed to clot at room temperature for about 1 hour, and
at 4°C overnight. Individual sera were tested by ELISA for
antibodies directed against chicken CII. In brief, ELISA
plates (Maxisorb; Nunc, Wiesbaden, Germany) were
coated overnight at 4°C with native CII (1 µg/ml; 100 µl per
well) in coating buffer (50 mM Tris-HCl, pH 8.5, 0.154 mM
NaCl), followed by incubation for 2 hours with blocking
buffer (50 mM Tris-HCl, pH 7.4, 0.154 mM NaCl and 0.1%
caseine) to saturate non-specific binding sites. Serial two-
fold dilutions of the sera in assay buffer (50 mM Tris-HCl,
pH 7.4, 154 mM NaCl and 0.05% Tween 20) were added
and incubated for 2 hours at room temperature. The plates
were then incubated for 2 hours with peroxidase-conju-
gated goat anti-mouse IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA). Finally, the substrate
3,3',5,5'-tetramethylbenzidine (Sigma-Aldrich) in reaction
buffer (100 mM sodium acetate/citric acid, pH 4.9) was
added for a 10 min incubation and absorbance was deter-
mined at 450 nm. Plates were washed five times between
each step with PBS containing 0.05% Tween 20. A serial
twofold dilution series of a purified standard was included
to permit a calculation of the antibody content of each sam-
ple. The standard was purified by affinity chromatography
from pooled sera obtained from various arthritic wild-type
and IFN-γR KO mice.
Quantitative RT-PCR
Isolated CD4+CD25+ and CD4+CD25- cells were pelleted
and directly used for total RNA isolation, using the Micro-
to-Midi Total RNA Purification System (Invitrogen Life
Technologies, Carlsbad, CA, USA). Total RNA (1 µg) was
used for random primed cDNA synthesis with RAV-2
reverse transcriptase (Amersham, Aylesbury, Bucks., UK).
The reaction mixture was incubated for 80 min at 42°C and
the reverse transcriptase was inactivated by incubating the
cDNA samples for 5 min at 95°C.
The cDNA samples were then subjected to real-time quan-
titative PCR, performed in the ABI prism 7700 sequence
detector (Applied Biosystems, Foster City, CA) as previ-
ously described [29]. The sequences of the forward (-FW)
and reverse (-RV) primers and probes (-TP) for β-actin and
Foxp3 were as follows: β-actin-FW, AGA GGG AAA TCG
TGC GTG AC; β-actin-RV, CAA TAG TGA TGA CCT
GGC CG T; β-actin-TP, CAC TGC CGC ATC CTC TTC
CTC CC; Foxp3-FW, CCC AGG AAA GAC AGC AAC
CTT; Foxp3-RV, TTC TCA CAA CCA GGC CAC TTG;
Foxp3-TP, ATC CTA CCC ACT GCT GGC AAA TGG
AGT C; TGF-β-FW, TGA CGT CAC TGG AGT TGT ACG
G; TGF-β-RV, GGT TCA TGT CAT GGA TGG TGC; TGF-
β-TP, TTC AGC GCT CAC TGC TCT TGT GAC AG.
Probes were dual-labelled with 5'-FAM and 3'-TAMRA.
All primers and probes were designed with the assistance
of the computer program Primer Express (AB) and were
purchased from Eurogentec (Seraing, Belgium). The 5'-
nuclease activity of the Taq polymerase was used to cleave
a nonextendable dual-labelled fluorogenic probe. Fluores-
cent emission was measured continuously during the PCR
reaction. PCR amplifications were performed in a total vol-
ume of 25 µl containing 5 µl of cDNA, 12.5 µl of Universal
PCR Master Mix, no AmpErase UNG (AB), each primer at
100 to 300 nM, and the corresponding detection probe at
200 nM. Each PCR amplification was performed in tripli-
cate wells under the following conditions: 94°C for 10 min,
followed by 40 or 45 cycles at 94°C for 15 s and 60°C for
1 min. cDNA plasmid standards, consisting of purified plas-
mid DNA specific for each individual target, were used to
quantify the target gene in the unknown samples, as
described [29]. All results were normalised to β-actin and/
or hypoxanthine–guanine phosphoribosyltransferase
(HPRT) to compensate for differences in the amount of
cDNA in all samples. Results were similar whether β-actin
or HPRT was used as the housekeeping gene.
Results
Effect of treatment in vivo with depleting anti-CD25 
antibodies on the development of CIA in wild-type DBA/
1 mice
In a first set of experiments we tested the importance of Treg
cells in the pathogenesis of CIA by rendering wild-type
mice deficient in Treg cells by treating the mice with deplet-
ing anti-CD25 antibody. Starting from day 11 or 13 after
immunisation with CII in CFA, wild-type DBA/1 mice were
treated every second day with anti-CD25 antibodies or
control IgG. In a first experiment, female mice were chosen
because these are only moderately sensitive to CIA
[30,31], so that we would be able to detect both increased
and decreased disease severity after CD25+ cell depletion.
Blood samples were taken at intervals to confirm the deple-
tion of the CD25+ population (Fig. 1a). In control-treated
mice, the development of arthritis (day of onset, incidence
and mean limb score) was reminiscent of our previously
reported findings in which mice received a single immuni-
sation with CII in CFA [20]. In contrast, mice treated with
the anti-CD25 antibodies developed a significantly moreAvailable online http://arthritis-research.com/content/7/2/R402
R406
Figure 1
Wild-type mice treated with anti-CD25 antibodies develop a more severe form of arthritis Wild-type mice treated with anti-CD25 antibodies develop a more severe form of arthritis. In three experiments, wild-type DBA/1 mice were immu-
nised on day 0 with collagen type II in complete Freund's adjuvant. From day 11 (c) or 13 (b) after immunisation onwards, mice were treated every 
second day with 0.25 mg of depleting anti-CD25 monoclonal antibody (N = 7) or with 0.25 mg control rat IgG (N = 7). (a) Depletion of the CD25+ 
cell population was checked in the blood twice a week by flow-cytometric analysis with anti-CD4 and anti-CD25 antibodies. A representative stain-
ing pattern on day 27 is shown. The percentages of CD4+CD25+ cells in control-treated mice (left plot) and anti-CD25-treated mice (right plot) are 
shown. (b, c) Cumulative incidence of arthritis (and mean day of disease onset) and the mean limb score of the arthritic mice in female (b) and male 
(c) wild-type mice treated with anti-CD25 or control IgG are shown (the maximum score per limb is 4). Error bars indicate SEM. The data from the 
female mice are representative of two independent experiments. The data of the three experiments were pooled and the percentage of limbs with 
each limb score on days 27 and 40 after immunisation is shown in (d). The mean limb score of the arthritic mice in the two groups is also indicated 
for the two time points and is significantly higher in the treated mice (P < 0.05; Mann–Whitney U-test) than in those receiving control IgG. (e, f) Rep-
resentative pictures of the most severe case of collagen-induced arthritis on day 25 after immunisation of a mouse treated with anti-CD25 (e) and a 
mouse treated with control IgG (f). (g) Haematoxylin-stained paraffin section of the joint of an anti-CD25-treated mouse on day 42 after immunisa-
tion. Hyperplasia and infiltration of immunocompetent cells in the synovium (s) and pannus formation (p) that penetrates into the bone (b) can be 
seen. Note the presence of osteoclast-like multinucleated giant cells (arrow). *P < 0.05 for comparison with control IgG1-treated mice (Mann–Whit-
ney U-test).Arthritis Research & Therapy    Vol 7 No 2    Kelchtermans et al.
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severe arthritis with a higher incidence and earlier onset
than those receiving control IgG1 (Fig. 1b). In fact, the dis-
ease course in antibody-treated mice was very similar to
that of IFN-γR KO mice [20-22]. The results were con-
firmed in an additional experiment with female mice. A third
experiment was also performed on male animals. The data
are plotted in Fig. 1c. Here again, anti-CD25-treated mice
developed a higher incidence and a more severe form of
arthritis than control-treated mice, whereas the onset of
arthritis was not significantly earlier (Fig. 1d). The data from
the three experiments were pooled and the percentages of
limbs with the different scores from only arthritic mice in the
two groups are shown in Fig. 1d. It can be seen that, at an
early time point (day 27 after immunisation), the highest
scores of arthritis (scores 3 and 4) were already present in
anti-CD25-injected mice, but not yet in their control coun-
terparts. On day 40 after immunisation, mice treated with
anti-CD25 developed more limbs with a maximum score of
4 than control-treated mice. The mean limb score on the
two days for the two groups are indicated and are signifi-
cantly different (P  < 0.05, Mann–Whitney U-test). The
mean number of involved limbs, ± SEM, on day 40 was 2.8
± 0.2 and 2.2 ± 0.2 for the treated and control mice,
respectively (P = 0.07; Mann–Whitney U-test). Represent-
ative pictures of the most severe case of arthritis of anti-
CD25-injected and control mice on day 25 after immunisa-
tion are shown in Fig. 1e and Fig. 1f, respectively. To
ensure that the more severe form of arthritis in the anti-
CD25-treated mice was not merely due to oedema, some
mice were killed at day 42 for histological evaluation. The
presence of hyperplasia and infiltration of immunocompe-
tent cells in the synovium, pannus formation and osteo-
clast-like multinucleated giant cells confirmed the
authenticity of arthritis (Fig. 1g).
On day 35 after immunisation, the titres of collagen-spe-
cific antibodies in the sera were determined. No differences
in antibody levels in sera of mice treated with anti-CD25 or
control IgG could be detected (data not shown).
Number and phenotype of CD4+CD25+ Treg cells in IFN-γR 
KO and wild-type mice
To test whether Treg cells might be less numerous in IFN-γR
KO than in wild-type mice – because this might explain the
differences in susceptibility to CIA – we counted
CD4+CD25+ cells in thymus, lymph nodes and spleen by
flow cytometry. IFN-γR KO and wild-type mice were immu-
nised with CII in CFA on day 0. Thymocytes, splenocytes
and lymph node cells were obtained on day 21, a time point
at which the difference in severity of arthritis between the
two groups of mice is most pronounced [20-22]. Groups of
naive IFN-γR KO and wild-type mice were also included. A
typical CD4/CD25 staining pattern of thymocytes and
lymph node cells from IFN-γR KO and wild-type mice is
shown in Fig. 2; percentages of CD4+CD25+  and
CD4+CD25- cells are indicated. It can be seen that IFN-γR
KO mice did not have smaller proportions of CD4+CD25+
cells in the thymus and lymph nodes. Immunised mice,
whether wild-type or IFN-γR KO, had rather lower propor-
tions of total CD4+ cells than naive counterparts (for exam-
ple 31% versus 50% in wild types). However, the real
numbers of CD4+ cells per organ were in fact higher after
immunisation and did not differ in IFN-γR KO from those in
wild-type mice. In fact, the lower percentages of CD4+ cells
after immunisation were due to a still larger expansion of
the myelopoietic population, a well-recognised phenome-
non arising from the use of CFA [22,32].
When over a total of six experiments (Table 1) the numbers
of CD4+CD25+ cells were expressed as fractions of total
CD4+ cell numbers, it appeared that spleens and lymph
nodes of IFN-γR KO mice, naive as well as immunised ones,
contained slightly higher percentages of CD4+CD25+
cells. In spleens and lymph nodes of wild-type mice, 5 to
10% of the CD4+ T cells were CD25+, conforming to pre-
viously published figures obtained in other mouse strains.
Thymuses contained lower percentages of CD4+CD25+
cells. A possible explanation might be that thymic CD4+ T
cell populations contain not only CD4+CD8-  but also
CD4+CD8+ cells, the latter being mostly CD25-. In the
peripheral lymphoid organs of IFN-γR KO mice, the per-
centage of CD4+CD25+ cells was higher (7 to 14%) than
in the wild-type mice (Table 1).
Because CD25 is expressed not only by Treg cells but also
by other recently activated T cells, the slightly higher pro-
portion of CD4+CD25+ cells in IFN-γR KO mice is not syn-
onymous with a higher proportion of Treg cells. In fact, even
a lower proportion of such cells cannot be excluded. We
therefore compared the CD4+CD25+ T cells from IFN-γR
KO and wild-type DBA/1 mice for expression of various
other activation markers. Figure 3a,b shows flow-cytomet-
ric expression patterns of CD69, CD62L, CD44 and cyto-
lytic T lymphocyte-associated antigen (CTLA-4) in
CD4+CD25+ T cells from naive and immunised IFN-γR KO
and wild-type mice. No major differences in expression lev-
els of these activation markers could be detected between
CD4+CD25+ T cells from IFN-γR KO mice and those from
wild-type mice, whether naive or immunised. Thus, this
analysis did not provide evidence for different proportions
of any cell type, including Treg cells. A specific marker for
Treg cells is Foxp3. We determined mRNA for this marker by
quantitative PCR in CD4+CD25+ and CD4+CD25- cells,
sorted from the lymph node cells of naive or immunised
IFN-γR KO and wild-type DBA/1 mice at day 21. In
CD4+CD25- cells Foxp3 mRNA levels were extremely low
(less than 6), and not different between one group of mice
and the other. CD4+CD25+ cells, in contrast, displayed
high expression levels. In cells from naive IFN-γR KO and
wild-type mice, levels were comparable. However,Available online http://arthritis-research.com/content/7/2/R402
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Figure 2
IFN-γ is not required to establish normal numbers of CD4+CD25+ Treg cells IFN-γ is not required to establish normal numbers of CD4+CD25+ Treg cells. Thymus cells (a) and lymph node cells (b) were isolated from IFN-γR KO 
and wild-type DBA/1 mice, either naive (upper row) or having been immunised 21 days previously with collagen type II in complete Freund's adjuvant 
(collagen-induced arthritis (CIA), lower row). Cells were stained with anti-CD25-FITC, phycoerythrin-conjugated anti-CD4 and propidium iodide. 
Dead cells were excluded by gating on propidium iodide-negative cells. The percentages of cells in each quadrant are indicated. Each plot repre-
sents a staining pattern of cells from a single female mouse. Identical profiles were observed in male mice. The staining pattern is representative of 
data obtained in three experiments (Table 1).
Table 1
Proportion of regulatory T cells to the total CD4+ T cell population in lymphoid organs of naive and immunised IFN-γ receptor knock-
out and wild-type (WT) DBA/1 mice
100 × CD4+CD25+/CD4+ (N)
Treatment Expt no. Organ IFN-γR KO WT
Naive 1 Thymus 3.2 ± 0.6 (5) 2.2 ± 0.7 (5)
Spleen 10.1 ± 0.9 (3) * 7.4 ± 0.2 (3)
Lymph nodes 6.9 ± 1.1 (5) 5.1 ± 1.1 (5)
2S p l e e n 1 4 . 4  ( 1 ) 9 . 9  ( 1 )
Lymph nodes 9.1 ± 0.9 (4) 6.6 ± 0.7 (4)
3 Lymph nodes 11.2 (1) 7.0 (1)
CIA 4 Thymus 3.5 ± 0.9 (3) 4.0 ± 1.6 (3)
Spleen 11.0 ± 1.3 (2) 7.9 ± 0.7 (2)
Lymph nodes 10.2 ± 0.8 (6) 7.7 ± 0.6 (6)
5 Spleen 12.1 ± 2.9 (3) 9.2 ± 0.8 (3)
Lymph nodes 12.9 ± 1.4 (4) 10.3 ± 1.1 (4)
6 Lymph nodes 13.4 ± 0.4 (4) * 9.2 ± 0.7 (4)
Cells were obtained from thymuses, spleens or lymph nodes of IFN-γ receptor knock-out (IFN-γR KO) and wild-type DBA/1 mice. In experiments 4 
to 6, mice were immunised with collagen type II in complete Freund's adjuvant on day 0, and cells were obtained on day 21 (collagen-induced 
arthritis; CIA). Cells were stained with anti-CD25-FITC and phycoerythrin-conjugated anti-CD4 antibodies. The proportion of CD4+CD25+ in the 
total CD4+ T cell population is shown. In experiments 1, 2, 4 and 5, N (number in parentheses) indicates the number of mice in each experiment; 
in experiments 3 and 6, N represents the number of experiments, each consisting of groups of 5 to 10 mice, from which samples were pooled for 
analysis. *Significant difference between IFN-γR KO and wild-type mice (P < 0.05; Mann–Whitney U-test).Arthritis Research & Therapy    Vol 7 No 2    Kelchtermans et al.
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CD4+CD25+ T cells of immunised IFN-γR KO mice con-
tained levels of Foxp3 that were one-third of those of wild-
type mice (Fig. 3c). This lower expression level might be
indicative of a smaller proportion of Treg cells in the sorted
CD4+CD25+ cell population or of a lower expression level
per cell. To distinguish between these alternatives, a tag-
ging anti-Foxp3 antibody would be needed.
Thus, after immunisation, IFN-γR KO mice possessed a
slightly higher percentage of CD4+CD25+ cells than wild-
type mice. However, the actual Treg cells present in this
population might be considerably less numerous or might
be qualitatively different so as to express less Foxp3.
Reduced suppressive activity of CD4+CD25+ Treg cells in 
arthritic IFN-γR KO mice
To characterise the CD4+CD25+ Treg cells functionally, we
measured their ability to suppress the anti-CD3-induced
proliferation of CD4+CD25- Teff cells in vitro. The experi-
ments were performed with CD4+CD25+  cells,
CD4+CD25- cells and ACs. Treg suppressive activity was
presented by plotting the percentage of inhibition against
the number of Treg cells. As shown in Fig. 4a,c, the patterns
of inhibition in naive IFN-gR KO and wild-type mice were
very similar: in both cases 2 × 104 purified CD4+CD25+
cells were able to inhibit more than 90% of the proliferative
response of 5 × 104 Teff cells. This result indicates that IFN-
γ is not required for Treg cells to be able to suppress anti-
CD3-induced in vitro proliferation.
In a separate set of seven experiments we investigated the
suppressive effect of CD4+CD25+ cells from mice that had
been immunised with CII in CFA. IFN-γR KO and wild-type
DBA/1 mice were immunised on day 0, and CD4+CD25+
cells, Teff cells and ACs were isolated on day 21 after immu-
nisation. The data of the individual experiments are plotted
in Fig. 4b and the means of the seven experiments are
shown in Fig. 4c. It can be seen that the capacity to sup-
press TCR-triggered proliferation of Teff cells was signifi-
cantly lower in CD4+CD25+ cells isolated from immunised
mice than in those of naive animals. Indeed, to obtain 40%
inhibition of proliferation, 4.5 × 103 CD4+CD25+ cells from
immunised wild-type mice were required, in comparison
with only 1.5 × 103 CD4+CD25+ cells from naive wild-type
mice. Moreover, CD4+CD25+ cells from immunised IFN-γR
KO mice were significantly less suppressive than those of
Figure 3
Phenotypic characterisation of CD4+CD25+ T cells from immunised IFN-γR KO and wild-type DBA/1 mice Phenotypic characterisation of CD4+CD25+ T cells from immunised IFN-γR KO and wild-type DBA/1 mice. (a, b) CD4+CD25+ T cells isolated from 
IFN-γR KO and wild-type mice show a similar expression pattern of activation markers, in naive (a) and immunised (b) conditions. CD4+ T cells were 
purified from the lymph node cells of eight IFN-γR KO and wild-type DBA/1 mice, either naive or having been immunised 21 days previously with col-
lagen type II in complete Freund's adjuvant (purity more than 99%). CD4+ T cells were stained for CD25 in combination with CD69, CD62L, CD44 
or cytolytic T lymphocyte-associated antigen-4 (CTLA-4). Dead cells were excluded by gating on propidium iodide-negative cells. The numbers rep-
resent the percentages of CD4+CD25+ cells within the indicated marker. (c) Decreased Foxp3 mRNA levels in CD4+CD25+ Treg cells from immu-
nised mice. Lymph node cells were isolated from eight naive or immunised IFN-γR KO and wild-type DBA/1 mice. Purified CD4+ T cells were stained 
with anti-CD25-FITC and phycoerythrin-conjugated anti-CD4, and sorted. The purity of the sorted CD4+CD25+ population was more than 97%. 
cDNA samples were prepared from 2 × 105 cells of each population and were subjected to real-time quantitative PCR analyses. The relative quantity 
of Foxp3 in each sample was normalised to the quantity of β-actin. Error bars indicate standard error of the means of two (CD4+CD24+ cells from 
naive mice) or three (CD4+CD25+ cells from immunised mice) independent experiments. *P < 0.05 for comparison with Foxp3 expression of cells 
isolated from immunised wild-type mice (Mann–Whitney U-test).Available online http://arthritis-research.com/content/7/2/R402
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immunised wild-type mice: 104 CD4+CD25+ cells were
necessary to decrease Teff cell proliferation by 40%. In an
additional experiment we verified whether the deficit in inhi-
bition by CD4+CD25+ cells from immunised IFN-γR KO
mice could be corrected by adding excess CD4+CD25+
cells. However, with 2 × 104 and 4 × 104 CD4+CD25+
cells the inhibition on T cell proliferation was 64.6% and
65.8%, respectively, indicating that a plateau level of sup-
pressive activity had been reached.
Normal levels of TGF-β in IFN-γR KO and wild-type mice
Several studies have shown the critical role of TGF-β in the
induction of Foxp3 and the activity of Treg cells [10,33,34].
Because IFN-γ and TGF-β act antagonistically with each
other (reviewed in [35]), it is possible that TGF-β is
upregulated in wild-type mice as a homeostatic response
to IFN-γ produced by their activated T cells, and similarly in
IFN-γR KO mice the decreased Foxp3 levels and the
decreased suppressive activity of Treg cells might be due to
inadequate amounts of TGF-β produced in the co-cultures
or in vivo in mice. We therefore analysed the expression of
TGF-β by quantitative PCR in Treg cells as well as in co-cul-
tures and in spleens of naive and immunised mice. The fol-
lowing results were obtained. First, the levels of TGF-β from
the sorted CD4+CD25+ cells from immunised IFN-γR KO
mice were not different from those of wild-type mice (nor-
malised TGF-β mRNA levels were 179 ± 16 and 193 ± 22,
respectively; mean ± SEM for three measurements).
Second, because TGF-β might be produced by ACs (or Teff
cells), quantitative PCR was performed on cells obtained
from co-cultures (Treg plus Teff plus ACs) from immunised
IFN-γR KO and wild-type mice. It was found that the levels
of TGF-β were even increased in IFN-γR KO cells in com-
parison with wild-type cells (2,184 versus 1,574, respec-
Figure 4
Suppressive capacity of CD4+CD25+ cells is decreased more in immunized IFN-γR KO than in wild-type mice Suppressive capacity of CD4+CD25+ cells is decreased more in immunized IFN-γR KO than in wild-type mice. (a, b) Treg cells, Teff cells and acces-
sory cells (ACs) were isolated from lymph nodes and spleen of naive (a) IFN-γR KO and wild-type DBA/1 mice or from IFN-γR KO and wild-type 
DBA/1 mice 21 days after immunisation with collagen type II in complete Freund's adjuvant (b). In each case, a group of seven to nine mice was 
used. CD4+CD25- Teff cells (5 × 104) were incubated with anti-CD3 antibody in the presence of ACs and the indicated number of CD4+CD25+ Treg 
cells. The percentage inhibition (100 × (Radioactivity in condition without Treg cells – Radioactivity in condition with Treg cells)/Radioactivity in condi-
tion without Treg cells) of the proliferation of Teff cells (CD4+CD25-) by increasing numbers of CD4+CD25+ Treg cells is shown. Two and seven inde-
pendent experiments are shown in (a) and (b), respectively. Each result is the mean of two cups. (c) The means of the two (naive mice) or seven 
(immunised mice) independent experiments shown in (a) and (b). Error bars indicate SEM.Arthritis Research & Therapy    Vol 7 No 2    Kelchtermans et al.
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tively, in the condition of 2 × 104 Treg cells, in a pool of eight
mice). Third, the TGF-β levels were also analysed ex vivo;
that is, in spleen tissue from IFN-γR KO and wild-type mice
at day 21 after immunisation (thus at a time point at which
Treg, Teff and ACs were isolated). Here again, the TGF-β lev-
els were found to be slightly increased in spleens from IFN-
γR KO mice (816 ± 129 and 633 ± 40 for IFN-γR KO and
wild-type mice, respectively). If these results are taken
together, the defective activity of Treg cells from arthritic
IFN-γR KO mice (in comparison with those from wild-type
animals) seems not to be associated with a defective TGF-
β production.
It was notable that the TGF-β levels were higher in immu-
nised mice than in their naive counterparts (for example,
633 ± 40 and 205 ± 19 for immunised and naive wild-type
mice, respectively). These data suggest that the differ-
ences in suppressive activity of Treg cells from immunised
versus naive mice cannot be explained by differences in the
TGF-β production.
Treg cells from immunised IFN-γR KO mice have the 
capacity to inhibit proliferation responses
We next investigated whether the lower capacity of
CD4+CD25+ cells from IFN-γR KO mice to downregulate
proliferation responses is due to an intrinsic defect or to an
altered activity of surrounding ACs and Teff cells. We meas-
ured the inhibition of anti-CD3-induced proliferation in co-
cultures differently reconstituted of CD4+CD25+,
CD4+CD25- and ACs, derived either from the same or from
different immunised wild-type or immunised IFN-γR KO
mice. The combinations tested are indicated in Fig. 5.
As expected, when all cells in the reconstituted co-cultures
were of IFN-γR KO mouse origin, suppressive activity was
less than when all cells were of wild-type origin. In co-cul-
tures of mixed composition, suppressive activity of IFN-γR
KO-derived CD4+CD25+ cells was less than that of the
wild type only when ACs were from IFN-γR KO origin, but
not when they were of wild-type origin. However, such ACs
of IFN-γR KO mice were unable to reduce the suppressive
effect of wild-type Treg cells against wild-type or IFN-γR KO
(data not shown) Teff cells. These data demonstrate that the
defect in inhibiting CD4+CD25- Teff cells acquired the pres-
ence of Treg cells from immunised IFN-γR KO mice in com-
bination with their autologous ACs.
Discussion
We and others have previously demonstrated that IFN-γ(R)
KO mice show an accelerated and more severe from of
arthritis than their wild-type counterparts, indicating that
endogenous IFN-γ acts as a protective factor in CIA
[20,21,24,25]. Because CIA has been defined as a Th1-
driven disease (reviewed in [17]), the protective effect of
IFN-γ in CIA constitutes an enigma that compromises the
Th1/Th2 paradigm as a basis for explaining the regulation
of autoimmune diseases. A clue to the enigma seemed to
be the use of CFA in the induction procedure of CIA. In the
absence of IFN-γ, CFA induces an extensive extramedullary
myelopoiesis that goes together with an even more pro-
nounced Th1 cytokine profile than in wild-type counterparts
[22,36]. The data suggest that IFN-γ can, under certain cir-
cumstances, be a strong Th2 inducer, a finding that has
recently been confirmed by others [37]. Here, we tested
the hypothesis that this protective action of IFN-γ is due to
a stimulatory effect on Treg cells. Specifically, we addressed
the following two questions. Are Treg cells important in mod-
ulating CIA? And, because we found that depletion of Treg
cells in wild-type mice increased the severity of CIA, can
the higher susceptibility of IFN-γR  K O  m i c e  t o  C I A  b e
explained by defects in the number or function of their Treg
cells?
As to the first question, we found that administration of a
Treg cell-depleting anti-CD25 antibody to wild-type DBA/1
mice after CFA-assisted immunisation with CII resulted in
Figure 5
Accessory cells (ACs) of immunised IFN-γR KO mice are required for  their defective Treg activity Accessory cells (ACs) of immunised IFN-γR KO mice are required for 
their defective Treg activity. Treg cells, Teff cells and ACs were isolated 
from lymph nodes and spleen of IFN-γR KO and wild-type DBA/1 mice 
21 days after immunisation with collagen type II in complete Freund's 
adjuvant. Mixing experiments were performed as indicated. In each set, 
5 × 104 CD4+CD25- Teff cells were incubated with anti-CD3 antibody in 
the presence of ACs and the indicated number of CD4+CD25+ Treg 
cells. The percentage inhibition of the proliferation of Teff cells 
(CD4+CD25-) by increasing numbers of CD4+CD25+ Treg cells is 
shown. The results are representative of two independent experiments.Available online http://arthritis-research.com/content/7/2/R402
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accelerated and more severe arthritis. In fact, the disease
course in these mice was comparable to that in IFN-γR KO
mice [20-23]. The actual depletion of Treg cells was moni-
tored by flow cytometry, and the authenticity of arthritis was
verified histopathologically. These results are in line with
those of Morgan and colleagues [26], who showed that the
administration of depleting anti-CD25 antibody before
immunisation (days –28, –24, –21 and –14) hastened the
onset of severe CIA. Because in our experiments antibod-
ies were administered starting from day 11 or day 13 after
immunisation, we can conclude that Treg cells are important
in the pathogenesis of CIA, not only in the immunisation
phase but also in the effector phase. In contrast to the find-
ings of Morgan and colleagues [26], the accelerated and
more severe course of arthritis was, in our experiments, not
accompanied by a higher concentration of anti-collagen II
antibodies, possibly due to the different regimen of anti-
CD25 treatment. Indirect evidence for the involvement of
Treg cells in the pathogenesis of CIA comes from data of
Min and colleagues [38]. They found that the immune toler-
ance induced by oral feeding of CII before induction of CIA
was mediated by IL-10-producing CD4+CD25+ T cells.
Notably, in proteoglycan-induced arthritis, another model of
autoimmune arthritis, it has been shown that CD4+CD25+
Treg cells might not have a critical role [39]. This might result
from the use of a different auto-antigen.
To address the second question, we compared
CD4+CD25+ cell numbers and Treg cell function in IFN-γR
KO DBA/1 mice with those in wild-type mice. According to
our hypothesis we expected numbers of Treg cells in IFN-γR
KO mice to be lower. Counter to this expectation, in each
of the six experiments done, we found a trend for a higher
proportion of CD4+CD25+ T cells in the total CD4+ cell
population. This was true for thymic, splenic and lymph
node CD4+ cells, in both naive and immunised mice. Anal-
ysis of all data as one set revealed a significant difference
of about 30% and 20% in naive and immunised mice,
respectively. CD25 is not an exclusive marker of Treg cells:
especially in immunised mice, part of the CD4+CD25+ pop-
ulation might be effector rather than regulatory T cells
[40,41]. Therefore, to exclude the possibility that we were
comparing two completely different populations, we per-
formed additional flow-cytometric characterisation studies
on pre-sorted CD4+CD25+ cells.
Expression of CD44, CD69, CTLA-4 and CD62L in
CD4+CD25+ cells from IFN-γR KO mice did not differ from
expression in cells from corresponding wild-type mice,
whether naive or immunised. However, because Treg cells
display an activated phenotype, activation markers might
not be adequate to distinguish Treg cells from activated Teff
cells. According to Fontenot and colleagues [42] a specific
marker for Treg cells is Foxp3, because it is highly expressed
in CD4+CD25+ Treg cells and is virtually undetectable in
both resting and activated Teff cells. We examined Foxp3
expression by determining mRNA levels with PCR. After
immunisation, CD4+CD25+ cells contained lower levels of
Foxp3 mRNA than those of their naive counterparts. More-
over, mRNA levels in immunised IFN-γR KO mice were less
than one-third of those in their wild-type counterparts, indi-
cating that IFN-γR KO mice have a smaller number of Treg
cells or that expression of Foxp3 in each Treg cell is lower.
Recently, Bruder and colleagues [43] have shown linked
expression of neuropilin-1 and Foxp3, thereby identifying
neuropilin-1 as a specific surface marker for CD4+CD25+
Treg cells able to distinguish them from both naive and
recently activated CD4+CD25+ non-regulatory T cells.
Nishibori and colleagues [44] demonstrated impaired
development of Treg cells in naive signal transduction and
activators of transcription (STAT)-1-deficient mice,
associated with an increased susceptibility to autoimmune
disease. Because IFN-γ is among the strongest activators
of STAT-1, these observations seem to conflict with ours.
However, several cytokines, other than IFN-γ, can also acti-
vate STAT-1, including IFN-α, IFN-β, IL-6, IL-9, IL-11,
oncostatin M, leukaemia inhibitory factor and the chemok-
ines RANTES and macrophage inflammatory protein 1α
[45,46].
To determine whether overall Treg cell activity would be
lower in IFN-γR KO mice, we co-cultured increasing
numbers of CD4+CD25+ T cells with fixed numbers of
CD4+CD25- Teff cells and ACs in the presence of anti-CD3
antibody. We observed a dose-dependent inhibition of the
proliferative responses by CD4+CD25+ Treg cells. By esti-
mating numbers of CD4+CD25+ cells required to attain a
selected level of suppression, we could compare suppres-
sive activity in the different groups of mice. In naive mice,
the inhibition curves were almost identical, whether the Treg
cells were derived from wild-type or IFN-γR KO mice, indi-
cating that endogenous IFN-γ is not an important regulator
of the function of constitutive CD4+CD25+ Treg cells. In co-
cultures of cells from immunised wild-type mice, the Treg
suppressive capacity was about one-third of that in those
from corresponding naive mice, and a further halving was
noted in co-cultures of cells from immunised IFN-γR KO
mice.
The observation that immunisation renders Treg cells less
suppressive is in line with results of Pasare and Medzhitov
[47], who found that microbial triggering of the Toll-like
receptor (TLR) pathway by lipopolysaccharide or CpG,
which are ligands for TLR4 and TLR9, respectively, blocked
the suppressive effect of CD4+CD25+ Treg cells. Because
mycobacteria also contain TLR ligands, immunisation with
CFA can be expected to affect Treg cell activity similarly. The
decrease in suppressive activity that takes place after TLR4Arthritis Research & Therapy    Vol 7 No 2    Kelchtermans et al.
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or TLR9 triggering was found to be dependent on IL-6 pro-
duction [47]. It might therefore be of interest to note that in
our experiments, IL-6 production was enhanced after expo-
sure to CFA-assisted immunisation, and this effect was
even more pronounced in IFN-γR KO mice (P Matthys,
unpublished data). This could provide an explanation for
the fact that CD25+ Treg cells are totally functional before
immunisation but lose (part of) their function after immuni-
sation. However, the most important observation is the
lower Treg suppressive capacity in IFN-γR KO than in wild-
type mice after CFA-assisted immunisation, because this
supports our hypothesis that the protective effect of
endogenous IFN-γ against CIA could be mediated in part
by its stimulatory effect on Treg cells.
Because the disease is barely detectable in wild-type mice
on day 21 after immunisation, we investigated whether the
decreased suppressive activity in immunised wild-type
mice was further downregulated at a later time point
(namely, day 35 after immunisation, when most of the ani-
mals show symptoms of arthritis). However, suppressive
activity was not further downregulated to the level seen in
homogeneous IFN-γR KO co-cultures, but was comparable
to that seen in co-cultures from immunised wild-type mice
on day 21 after immunisation (maximal inhibition 60%; data
not shown). This indicates that the low suppressive activity
as evident in immunised IFN-γR KO mice is restricted to
conditions under which IFN-γ is abrogated.
The implication is that the CIA immunisation schedule
induces a decrease in Treg activity and that endogenous
IFN-γ largely counteracts this decrease. It therefore
becomes important to know by what mechanism, direct or
indirect, IFN-γ influences Treg cell function. Addition of anti-
IFN-γ antibody to the co-cultures failed to affect suppres-
sive activity (data not shown), indicating that the relevant
IFN-γ effect takes place in vivo before sampling of the T
cells. To examine the role of the different cell components,
we tested suppressive activity in mixed co-cultures.
CD4+CD25+ cells from immunised IFN-γR KO mice, con-
fronted with Teff cells and ACs from immunised wild-type
mice, were not less suppressive than wild-type
CD4+CD25+ confronted with wild-type or IFN-γR KO Teff
cells and ACs. This suggests that lower levels of suppres-
sion in homogeneous IFN-γR KO cultures result in part from
the presence of IFN-γR KO-derived ACs. And, indeed,
when CD4+CD25+ and Teff cells from immunised IFN-γR
KO mice were co-cultured with ACs from immunised wild-
type mice, suppressive activity was not inhibited. Finally,
ACs from IFN-γR KO mice by themselves were unable to
downregulate the activity of wild-type Treg cells acting on
wild-type Teff cells. We therefore conclude that the in vivo
effect of endogenous IFN-γ that accounts for the greater
suppressive activity in wild-type mice than in IFN-γR KO
mice concerns reprogramming of both ACs and Treg cells.
Because CD4+CD25+ T cells from immunised IFN-γR KO
mice were not less suppressive than those of immunised
wild-type mice in co-cultures with Teff cells and ACs from
immunised wild-type mice, we can refute the proposition
that the lower expression of Foxp3 in the CD4+CD25+ pop-
ulation from immunised IFN-γR KO mice is due to a smaller
proportion of Treg cells and a larger number of activated Teff
cells. Indeed, if the CD4+CD25+  population from
immunised IFN-γR KO mice contained a higher proportion
of activated Teff cells, suppression by these CD4+CD25+
cells should be lower, irrespective of the origin of the Teff
cells and ACs. Another argument is that the addition of
more CD4+CD25+ cells failed to improve suppression in
co-cultures of cells from immunised IFN-γR KO mice. Our
data are therefore more in line with the proposition of a
lower Foxp3 expression level per cell.
Expression of Foxp3 could be downregulated by the inter-
action of Treg cells with ACs. ACs might be source of TGF-
β, which has been described to convert naive T cells into
CD25+ suppressor cells by inducing Foxp3 expression
[48]. Because IFN-γ and TGF-β act antagonistically with
each other, the low levels of Foxp3 in arthritic IFN-γR KO
mice might be due to inadequate amounts of TGF-β pro-
duced by ACs or other cells. However, quantitative PCR
performed on isolated Treg cells, on cells obtained from co-
cultures (Treg plus Teff plus ACs) and on splenocytes from
immunised IFN-γR KO and wild-type mice does not support
the concept that the defective activity of Treg cells in vitro or
in vivo is due to defects in the production of TGF-β. ACs
have also been shown to be able to reverse suppression by
CD4+CD25+ cells through the GITR/GITR-ligand system
[49]. GITR (glucocorticoid-induced tumour necrosis factor
receptor) is expressed on CD4+CD25+ T cells; GITR-lig-
and is initially upregulated on activated APCs. It remains to
be determined whether this process involves a downregu-
lation of Foxp3 expression. This or a similar mechanism
might take place during the interaction of Treg cells and ACs
from immunised IFN-γR KO mice. Co-cultures with ACs of
immunised wild-type mice might possibly normalise Foxp3
expression in the Treg cells of immunised IFN-γR KO mice,
together with their Treg suppressive activity.
Conclusions
In conclusion, our experiments support a pathogenesis
model that ascribes an important role to Treg cells as mod-
erators of the disease course in CIA. In particular we show
that Treg cells fulfil this role not only during the induction
phase but also during the effector phase of the autoimmune
response. Furthermore, we were able to refine the model by
showing that, after the immunisation with CII in CFA, Treg
cells lose part of their suppressive potential. This effect is
more pronounced in IFN-γR KO than in wild-type mice, indi-
cating that, in this system, IFN-γ acts as an upregulator of
Treg activity, which might be part of the explanation for theAvailable online http://arthritis-research.com/content/7/2/R402
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well-known protective effect of endogenous IFN-γ. Finally,
we present evidence that the mechanism underlying the
effect of IFN-γ on Treg cell activity is exerted in part via ACs.
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